These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16580601)

  • 1. Targeting N-type and T-type calcium channels for the treatment of pain.
    McGivern JG
    Drug Discov Today; 2006 Mar; 11(5-6):245-53. PubMed ID: 16580601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Ca2+ channels to treat pain: T-type versus N-type.
    Altier C; Zamponi GW
    Trends Pharmacol Sci; 2004 Sep; 25(9):465-70. PubMed ID: 15559248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ziconotide: can we use it in palliative care?
    Prommer EE
    Am J Hosp Palliat Care; 2005; 22(5):369-74. PubMed ID: 16225359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voltage gated calcium channels as targets for analgesics.
    Bourinet E; Zamponi GW
    Curr Top Med Chem; 2005; 5(6):539-46. PubMed ID: 16022676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting chronic and neuropathic pain: the N-type calcium channel comes of age.
    Snutch TP
    NeuroRx; 2005 Oct; 2(4):662-70. PubMed ID: 16489373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analgesic (omega)-conotoxins CVIE and CVIF selectively and voltage-dependently block recombinant and native N-type calcium channels.
    Berecki G; Motin L; Haythornthwaite A; Vink S; Bansal P; Drinkwater R; Wang CI; Moretta M; Lewis RJ; Alewood PF; Christie MJ; Adams DJ
    Mol Pharmacol; 2010 Feb; 77(2):139-48. PubMed ID: 19892914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Voltage-gated calcium channels in chronic pain: emerging role of alternative splicing.
    Swayne LA; Bourinet E
    Pflugers Arch; 2008 Jun; 456(3):459-66. PubMed ID: 18389277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peptide leads new class of chronic pain drugs.
    Garber K
    Nat Biotechnol; 2005 Apr; 23(4):399. PubMed ID: 15815650
    [No Abstract]   [Full Text] [Related]  

  • 9. Scaffold-based design and synthesis of potent N-type calcium channel blockers.
    Zamponi GW; Feng ZP; Zhang L; Pajouhesh H; Ding Y; Belardetti F; Pajouhesh H; Dolphin D; Mitscher LA; Snutch TP
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6467-72. PubMed ID: 19815411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elan: ziconotide review focused on off-label uses.
    Narayana AK
    Am J Hosp Palliat Care; 2005; 22(6):408. PubMed ID: 16323709
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of ω-conotoxin MVIIA and Phα1β on paclitaxel-induced acute and chronic pain.
    Rigo FK; Dalmolin GD; Trevisan G; Tonello R; Silva MA; Rossato MF; Klafke JZ; Cordeiro Mdo N; Castro Junior CJ; Montijo D; Gomez MV; Ferreira J
    Pharmacol Biochem Behav; 2013 Dec; 114-115():16-22. PubMed ID: 24148893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Huwentoxin-XVI, an analgesic, highly reversible mammalian N-type calcium channel antagonist from Chinese tarantula Ornithoctonus huwena.
    Deng M; Luo X; Xiao Y; Sun Z; Jiang L; Liu Z; Zeng X; Chen H; Tang J; Zeng W; Songping Liang
    Neuropharmacology; 2014 Apr; 79():657-67. PubMed ID: 24467846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An integrated multiassay approach to the discovery of small-molecule N-type voltage-gated calcium channel antagonists.
    Finley MF; Lubin ML; Neeper MP; Beck E; Liu Y; Flores CM; Qin N
    Assay Drug Dev Technol; 2010 Dec; 8(6):685-94. PubMed ID: 21050074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting voltage-gated calcium channels for the treatment of neuropathic pain: a review of drug development.
    Pexton T; Moeller-Bertram T; Schilling JM; Wallace MS
    Expert Opin Investig Drugs; 2011 Sep; 20(9):1277-84. PubMed ID: 21740292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropathic pain: role of voltage-dependent calcium channels.
    Chaplan SR
    Reg Anesth Pain Med; 2000; 25(3):283-5. PubMed ID: 10834784
    [No Abstract]   [Full Text] [Related]  

  • 16. Ziconotide: neuronal calcium channel blocker for treating severe chronic pain.
    Miljanich GP
    Curr Med Chem; 2004 Dec; 11(23):3029-40. PubMed ID: 15578997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent progress in the discovery and development of N-type calcium channel modulators for the treatment of pain.
    Lee MS
    Prog Med Chem; 2014; 53():147-86. PubMed ID: 24418610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides.
    Feldman P; Khanna R
    Neurosci Lett; 2013 Dec; 557 Pt A(0 0):27-36. PubMed ID: 23831344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-type calcium channel blockers: a call for papers.
    Baumrucker SJ
    Am J Hosp Palliat Care; 2005; 22(2):91-2. PubMed ID: 15853084
    [No Abstract]   [Full Text] [Related]  

  • 20. Analgesic effects of a substituted N-triazole oxindole (TROX-1), a state-dependent, voltage-gated calcium channel 2 blocker.
    Abbadie C; McManus OB; Sun SY; Bugianesi RM; Dai G; Haedo RJ; Herrington JB; Kaczorowski GJ; Smith MM; Swensen AM; Warren VA; Williams B; Arneric SP; Eduljee C; Snutch TP; Tringham EW; Jochnowitz N; Liang A; Euan MacIntyre D; McGowan E; Mistry S; White VV; Hoyt SB; London C; Lyons KA; Bunting PB; Volksdorf S; Duffy JL
    J Pharmacol Exp Ther; 2010 Aug; 334(2):545-55. PubMed ID: 20439438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.